Renal Cell Carcinoma

During a Targeted Oncology case-based roundtable event, Jad Chahoud, MD, MPH, discussed the case of a patient who progresses while on pembrolizumab plus axitinib, then again while on cabozantinib.

Type C meeting with the FDA requested by Allarity to discuss potential clinical paths to support approval of dovitinib as a potential option in the third-line treatment of patients with renal cell carcinoma

According to Primo Nery Lara, Jr, MD, frontline treatment options for metastatic renal cell carcinoma have been improving rapidly.

Nazli Dizman, MD, explains that gut microbiome diversities play a large role in modulating response to immunotherapy.

Showing similarity to results from CheckMate 214, findings from CheckMate 920 shows that nivolumab plus ipilimumab can safety be administered to patients with non-clear cell renal cell carcinoma.

In an interview with Targeted Oncology, Chung-Han Lee, MD, PhD further discussed the results of the phase 2 trial of the combination of cabozantinib and nivolumab in patients with metastatic non-clear cell RCC and how it impacts the future of this space.

Oncologists at FCS, Lucio N. Gordan, MD and Ivor Percent, MD have published findings from the CheckMate 920 clinical trial.

A multivariate analysis of response rates of patients with metastatic renal cell carcinoma identified which factors are associated with a partial or complete response to first-line doublet immunotherapy or immunotherapy/tyrosine kinase inhibitor combinations.

Naomi B. Haas, MD, discusses the use of VEGF tyrosine kinase inhibitors as neoadjuvant therapy for renal cell carcinoma.

Updated data from the ongoing phase 1b/2 trial of batiraxcept in combination with cabozantinib shows favorable outcomes in patients with clear cell renal cell carcinoma.

A biotherapeutic led to improved efficacy of immunotherapy in a phase 1 study of patients with metastatic renal cell carcinoma.

During a live virtual event, Moshe Ornstein, MD, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and participants' experiences with these agents.

A reduction in cabozantinib dosage because of toxicity shows improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.

In an interview with Targeted Oncology, Vitaly Margulis, MD, discussed the function and findings of metabolomics in renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Scott Tykodi, MD, PhD, discussed the data supporting various treatment options for renal cell carcinoma with participants.

Updated findings from the phase 3 KEYNOTE-564 trial may further support adjuvant pembrolizumab as a new standard of care for patients with renal cell carcinoma with high risk of recurrence.

NeoAvAx trial results show that neoadjuvant avelumab/axitinib may be beneficial to patients with renal cell carcinoma.

A 3-year analysis of updated data from the phase 3 CheckMAte 9ER trial shows the better health-related quality of life outcomes for patients with advanced renal cell carcinoma on nivolumab plus cabozantinib.

A subgroup analysis of lenvatinib plus pembrolizumab showed similar results to the global population of patients with advanced renal cell carcinoma who participated in the phase 3 CLEAR trial.

Three immune cell-related factors appear to impact response or lack of response to treatment with nivolumab plus ipilimumab in patients with advanced or metastatic renal cell carcinoma.

In a final overall survival analysis of CheckMate 9ER, investigators saw a continued survival benefit with first-line nivolumab plus cabozantinib compared with sunitinib in the intention-to-treat patients with untreated clear cell metastatic or advanced renal cell carcinoma.

Tivozanib as first-line treatment showed noninferiority compared with other tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma in a real-world setting. This is an attractive option for patients due to tivozanib’s tolerable safety profile.

Lenvatinib in combination with pembrolizumab demonstrated clinical benefit in patients with advanced renal cell carcinoma regardless of their biomarker status.

Time to event end points and response rates were similar regardless of which first-line immunotherapy was administered, according to an analysis conducted by the International Metastatic Renal Cell Carcinoma Database Consortium

New data presented during the Genitourinary Cancers Symposium support the using cabozantinib after immunotherapy without new safety signals.